Glaukos Corporation (GKOS) Scheduled to Post Earnings on Tuesday
Glaukos Corporation (NYSE:GKOS) is scheduled to post its quarterly earnings results after the market closes on Tuesday, November 7th.
Shares of Glaukos Corporation (NYSE GKOS) traded down 0.45% during midday trading on Tuesday, reaching $35.19. 518,707 shares of the company were exchanged. The company’s market capitalization is $1.21 billion. The stock’s 50-day moving average price is $33.84 and its 200-day moving average price is $33.84. Glaukos Corporation has a 52-week low of $28.72 and a 52-week high of $52.49.
ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/31/glaukos-corporation-gkos-scheduled-to-post-earnings-on-tuesday.html.
Several analysts recently weighed in on the stock. BidaskClub upgraded shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, September 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $60.00 target price (up from $54.00) on shares of Glaukos Corporation in a report on Thursday, September 14th. Zacks Investment Research downgraded shares of Glaukos Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Piper Jaffray Companies reiterated a “buy” rating and issued a $56.00 target price on shares of Glaukos Corporation in a report on Thursday, August 3rd. Finally, Roth Capital dropped their target price on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $48.57.
In related news, Director Orbimed Advisors Llc sold 325,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $37.93, for a total transaction of $12,327,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas William Burns sold 73,788 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $41.36, for a total transaction of $3,051,871.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 980,200 shares of company stock valued at $37,900,263. Corporate insiders own 16.40% of the company’s stock.
Glaukos Corporation Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.